Press Releases

Blue Coat is One of the Most User-Friendly Offerings in This Space

SUNNYVALE, Calif.--(BUSINESS WIRE)-- Blue Coat Systems, Inc. (Nasdaq: BCSI), the technology leader in Application Delivery Networking, today announced that it has "scored strongest among leaders" in the newly issued November 2009 The Forrester Wave(TM): WAN Optimization, Q4 2009. According to the report, Blue Coat "scored strongest" among the eight vendors evaluated in the WAN optimization market.

The report states that Blue Coat appliances are "one of the most user-friendly offerings in this space, with policy and configuration templates and wizards, device auto-discovery, automated device configuration, and an object-oriented or visual policy manager, along with a basic startup time of 66 seconds." Forrester further states that by "leveraging its PacketShaper product, Blue Coat allows for identification of applications, enhancing the visibility of traffic due to its ability to classify more than 600 applications along with the ability to add classifications for custom applications, defined by the administrator -- making Blue Coat a clear leader in application visibility in the WAN optimization market."

"We believe achieving a leading position in the Forrester Wave(TM) report, WAN Optimization, Q4 2009 recognizes the unique approach Blue Coat has applied to WAN optimization by first starting with application visibility and then applying acceleration, security or control technologies as appropriate to the nature or business value of the application or content," said Bethany Mayer, senior vice president, Worldwide Marketing and Corporate Development for Blue Coat Systems. "WAN optimization is no longer about blind, indiscriminate acceleration but, rather, optimizing and securing the flow of information to any user, on any network, anywhere."

To access a complimentary copy of the report, please visit: www.bluecoat.com/doc/12527.

About Blue Coat Systems

Blue Coat Systems is the technology leader in Application Delivery Networking. Blue Coat offers an Application Delivery Network Infrastructure that provides the visibility, acceleration and security required to optimize and secure the flow of information to any user, on any network, anywhere. This application intelligence enables enterprises to tightly align network investments with business requirements, speed decision making and secure business applications for long-term competitive advantage. For additional information, please visit www.bluecoat.com.

FORWARD LOOKING STATEMENTS: The statements contained in this press release that are not purely historical are forward-looking statements, including statements regarding Blue Coat Systems' expectations, beliefs, intentions or strategies regarding the future, and including statements regarding the capabilities and expected performance of Blue Coat Systems' products. All forward-looking statements included in this press release are based upon information available to Blue Coat Systems as of the date hereof, and Blue Coat Systems assumes no obligation to update any such forward-looking statements. Forward-looking statements involve risks and uncertainties, which could cause actual results to differ materially from those projected. These and other risks relating to Blue Coat Systems' business are set forth in the Securities and Exchange Commission reports filed by Blue Coat Systems, including but not limited to the risks described in the most recent reports on Form 10-K and Form 10-Q, particularly under the heading "Risk Factors."

Blue Coat, ProxySG and the Blue Coat logo are registered trademarks or trademarks of Blue Coat Systems, Inc. and/or its affiliates in the United States and certain other countries. All other trademarks mentioned in this document are the property of their respective owners.

    Source: Blue Coat Systems, Inc.

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/234cd9/social_network_con) has announced the addition of eMarketer's new report "Social Network Content: Are Users Willing to Pay?" to their offering.

On September 15, 2009, Facebook CEO Mark Zuckerberg announced that the social network had surpassed the 300-million-member mark and reached cash-flow-positive status for the first time. Those milestones validated Facebook's core concept of monetizing its service through advertising, and revived a lingering question that has swirled around social networking since its inception: Will users pay for content?

A close look at the social network landscape reveals that beyond mainstream sites such as Facebook and MySpace, paid content is alive and well. Networks that cater to market niches have particularly thrived on hybrids of paid models and ad-based systems. Some of these players, such as LinkedIn, Classmates.com and MyLife.com, are earning at least as much revenue from fee-based content and services as from advertising.

As the online ad market continues to struggle, paid services including membership fees, premium features and virtual goods will take on increasing urgency for social networks, either as primary revenue generators or ancillary income sources.

Key Questions:

    --  Are social network users willing to pay for content?
    --  What is the revenue outlook for paid social networking sites?
    --  What are the prospects for Facebook and Twitter charging their users?
    --  What strategies work for paid-content providers when ad-supported
        competitors enter the fray?

Key Topics Covered:

Executive Summary

    --  Us Paid Social Networking Site Revenues, 2008-2013 (Millions And %
        Change)

Key Questions

Paid Social Network Content

    --  Us Paid Social Networking Site Revenues, 2008-2013 (Millions And %
        Change)
    --  Us Online Social Network Advertising Spending, 2008-2011 (Millions And %
        Change)
    --  Best Way To Monetize Social Media According To Social Media Leaders In
        North America, February 2009 (% Of Respondents)
    --  Social Media Service For Which Social Media Leaders In North America
        Would Most Likely Pay, February 2009 (% Of Respondents)
    --  Social Media Service For Which Social Media Leaders In North America
        Would Advise A Business To Pay, February 2009 (% Of Respondents)

Competitive Strategies: Paid Vs. Free

Will Facebook And Twitter Charge Users?

    --  Us Adult Twitter Users, 2008-2010 (Millions And % Of Adult Internet
        Users)

Paid Services On Niche Networks

Controversies Over Paid Services

Conclusions

Endnotes

For more information visit http://www.researchandmarkets.com/research/234cd9/social_network_con

    Source: Research and Markets

MINNEAPOLIS, Nov. 11 /PRNewswire/ -- Zepol Corporation, a trade data intelligence company, today announced the launch of an upgrade of its flagship product, TradeIQ(TM). This upgrade includes adding several features that increase customer usability and revamping the product's download capabilities for the U.S. Customs data it provides. With these changes to the trade data industry's fastest application, Zepol now offers four subscription options for importers, NVOCCs, law firms, and trade specialists from many industries.

"We have always strived to provide the best trade data tools in the marketplace, these improvements will help our users save hours of work over the course of their subscription when compared with other tools available," declared Paul Rasmussen, CEO & President of Zepol Corporation. "I am incredibly proud of our development team for creating these innovative enhancements, and to ensure all companies in the market have access to one of our subscriptions, we are expanding our subscription offerings."

TradeIQ(TM) subscriptions can be purchased at http://www.zepol.com and are available through several options designed to meet the specific needs of different segments of the market. With annual access starting at $1,995 with Flex and $2,995 for Lite, Zepol's subscription options offer the latest information on competitors' and suppliers' imports at a price point accessible for most small and mid-sized importers and transportation companies. Zepol's Professional subscription provides comprehensive access to all trade data available from the U.S. government including U.S. Customs data and U.S. Census data with annual access for $5,995. Enterprise is Zepol's solution for companies with many users across their organizations and starts at $7,595.

Zepol's newest release of TradeIQ(TM) follows a pattern of continuous improvement to meet customers' needs. In addition to increasing usability and download capabilities, Zepol will soon provide searches that will break new ground in the trade data industry and ensure accuracy that many users have not achieved with other providers at both an aggregate and detailed level of trade.

About Zepol Corporation:

Zepol Corporation is a Minnesota-based company working to provide the most complete and up-to-date trade data to organizations around the world. Zepol provides industry leading trade data tools, TradeIQ(TM) and TradeView(TM), for analyzing the United States trade marketplace. TradeIQ(TM) is an up-to-date U.S. Customs import Bill of Lading database and is available through an online interface. TradeView(TM) provides access to U.S. Census data to visualize the import and export economy.

    Contact:

    Kevin Palmstein
    Zepol Corporation
    Tel: 612.435.2194
    kevin.palmstein@zepol.com
    http://www.zepol.com

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.

SOURCE Zepol Corporation

NEW YORK--(BUSINESS WIRE)-- ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), a biopharmaceutical company that is seeking to develop and commercialize a diverse, risk sensitive portfolio of in-licensed cancer drugs addressing unmet medical needs, today reported its financial results for the quarter ended September 30, 2009 and provided an update on the Company's clinical programs.

The Company reported a net loss for the third quarter 2009 of $2.9 million, or $(0.13) per share, compared with a net loss for the third quarter of 2008 of $5.5 million, or $(0.26) per share. The significant decrease in operating expenses is attributable to a continuing focus of resources as well as tight management of operating expenses. For the third quarter of 2009, as compared to 2008, Research and Development expenses declined $2.6 million while General and Administrative expenses declined by $0.4 million. Net cash used in operations was $2.1 million in the third quarter of 2009 as compared with $5.9 million during the comparable 2008 period. The decrease in net cash used in operations was primarily attributable to a decrease in net loss of $2.7 million. Net cash used in operations for the nine months ended September 30, 2009 and 2008 was $8.9 million and $19.7 million, respectively. Again, the decrease in net cash used in operations was primarily attributable to a decrease in the net loss of $12.0 million. The Company ended the September 2009 quarter with cash of approximately $7.1 million which is expected to support operations into the second quarter of 2010.

During the third quarter, the company completed an offering of its common stock and warrants resulting in net proceeds of approximately $4.6 million after paying offering expenses of $0.5 million.

The Company's clinical programs have progressed well. The palifosfamide (ZymafosTM, ZIO-201) randomized Phase II trial in metastatic or unresectable soft tissue sarcoma achieved the study-specified efficacy milestone following planned safety and efficacy review by the Data Committee, a panel of international sarcoma experts, and the Company's Medical Advisory Board. It was determined that the data are compelling and sufficient to proceed to a pivotal study in support of product registration and to conclude enrollment. The company is in dialogue with the U.S. Food and Drug Administration (FDA) on the design and implementation of a registration trial, a study the Company expects could initiate as early as the first half of 2010. The Company is also in dialogue with FDA on the intravenous Phase II darinaparsin (ZinaparTM or ZIO-101) study results in lymphoma with the intent of conducting a registration trial in peripheral T-cell lymphoma, also as early as the first half of 2010. The oral darinaparsin Phase I trials continue enrollment in order to establish the best dose and schedule. Oral indibulin (ZybulinTM or ZIO-301) is scheduled to enter into a Phase I/II study in breast cancer patients using the Norton-dosing schedule developed preclinically with Dr. Larry Norton and initiating in early 2010 with the teams of Dr. Clifford Hudis (Memorial Sloan-Kettering Cancer Center) in the United States and Dr. Jose Baselga (Vall d'Hebron University Hospital) in Spain.

About ZIOPHARM Oncology, Inc.:

ZIOPHARM Oncology is a biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of cancer drugs. The Company is currently focused on three clinical programs.

Palifosfamide (ZymafosTM or ZIO-201) references a novel composition (tris formulation) that is the functional active metabolite of ifosfamide, a standard of care for treating sarcoma, lymphoma, testicular, and other cancers. Palifosfamide delivers only the cancer fighting component of ifosfamide. It is expected to overcome the resistance seen with ifosfamide and cyclophosphamide, two of the most commonly used alkylating drugs used to treat certain cancers. Palifosfamide does not have the toxic metabolites of ifosfamide that cause the debilitating side effects of "fuzzy brain" (encephalopathy) and severe bladder inflammation. Intravenous palifosfamide is currently in a randomized Phase II trial to treat unresectable or metastatic soft tissue sarcoma in the front- and second-line setting, a study expected to establish the basis for a registration trial as early as the first half of 2010. An oral form of palifosfamide has been developed preclinically to the investigational new drug application stage.

Darinaparsin (ZinaparTM or ZIO-101) is a novel organic arsenic being developed for the treatment of various hematologic and solid cancers. Preclinical and clinical studies to date have demonstrated that darinaparsin is considerably less toxic than inorganic arsenic, particularly with regard to cardiac toxicity. Phase I and Phase II testing of the intravenous form of darinaparsin in solid tumors and hematological cancers has been completed or is nearing completion. The Company has reported clinical activity and, importantly, a safety profile from these studies as predicted by preclinical results. Favorable results from the trial with IV-administered darinaparsin in lymphoma, particularly peripheral T-cell lymphoma ("PTCL"), were reported at the American Society of Clinical Oncology (ASCO) in May. Supported by these data, the Company expects to advance into a registration trial in peripheral T-cell lymphoma as early as the first half of 2010. Also as reported at ASCO, in ongoing Phase I trials the oral form is active and well tolerated.

Indibulin (ZybulinTM or ZIO-301) is a novel, oral tubulin binding agent that targets both mitosis and cancer cell migration. Indibulin is expected to have several potential benefits, including oral dosing, application in multi-drug resistant tumors, no neuropathy and minimal overall toxicity. In multiple Phase I trials in cancer patients, oral indibulin has been administered both as a single agent and in combination with favorable activity and a promising safety profile that does not include the neurotoxicity seen with all of the other classes of tubulin binding agents. Most recently, results of oral indibulin in combination with oral capecitabine (Xeloda(R)) were presented at this year's American Society of Clinical Oncology (ASCO) along with the preclinical findings of a novel dosing schedule conducted under the direction of Dr. Larry Norton. The Company expects to initiate a Phase I/II study of oral indibulin in breast cancer patients employing this dosing schedule established preclinically. Once the maximum tolerated dose is established in the Phase I portion of the trial, Phase II will proceed with an expanded population.

ZIOPHARM's operations are located in Boston, MA with an executive office in New York City. Further information about ZIOPHARM may be found at www.ziopharm.com.

ZIOP-E

Forward-Looking Safe Harbor Statement:

This press release contains forward-looking statements for ZIOPHARM Oncology, Inc. that involve risks and uncertainties that could cause the Company's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurance that any of the Company's development efforts relating to its product candidates will be successful, or such product candidates will be successfully commercialized. Other risks that affect forward-looking information contained in this press release include the possibility of being unable to obtain regulatory approval of the Company's product candidates, the risk that final trial data may not support interim analysis and that the results of clinical trials in general may not support the Company's claims, risks related to the Company's ability to protect its intellectual property, risks related to its reliance on third parties to develop its product candidates, risks related to the sufficiency of existing capital reserves to fund continued operations for a particular amount of time and uncertainties regarding the Company's ability to obtain additional financing to support its operations thereafter. The Company assumes no obligation to update these forward-looking statements, except as required by law.

    Source: ZIOPHARM Oncology, Inc.

SANTA MONICA, Calif.--(BUSINESS WIRE)-- Ecologic Transportation, Inc. ("Ecologic Transportation" or the "Company") (OTCBB: EGCT) today announced it formed a joint venture with Ray Motor Ltd, an Israeli company with principal place of business located at Kibbutz Magshimim, Israel, to identify and contract with potential business partners in Israel to operate electric car rental operations under the Ecologic Brand.

Ray Motors Ltd. has over 200 years of combined automotive experience including R&D, engineering, prototyping, and mass production for special applications. Ray Motor's principals are the founders of TOMCAR, joined by several electric vehicle specialists in developing cutting edge solutions for this industry.

"This joint venture aligns with Ecologic Transportation's strategy to introduce customers to environmentally friendly vehicles - to get green cars into the hands of a growing demographic - those car rental customers who are unattached to a brand, but attached to an idea," said William N. Plamondon III, President and CEO of Ecologic Transportation. "There is a high demand for electric vehicles in Israel, so this joint venture gives us a great opportunity to export the Ecologic brand."

ABOUT ECOLOGIC TRANSPORTATION, INC.

Headquartered in Santa Monica, CA, Ecologic Transportation, Inc., is a holding company with wholly owned subsidiaries all dedicated to environmentally friendly transportation products and services. The company encompasses three separate but integrated operations that address the environment and transportation holistically: Ecologic Car Rentals, Ecologic Systems and Ecologic Products. This innovative company has an unbiased approach to green cars and clean fuels by providing a platform for all emerging environmental transportation technologies. For more information: www.ecologictransportation.com. For more news and information on Ecologic Transportation, please visit http://www.myshareholder.com/ecologic-transportation.html where you can follow Ecologic on Facebook, Twitter, and You Tube.

FORWARD-LOOKING STATEMENTS

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our reports filed with the SEC. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

    Source: Ecologic Transportation, Inc.